Semaglutide May Be a Better Fit For: Individuals sensitive to gastrointestinal side effects Those needing moderate appetite regulation rather than maximal suppression People prioritizing long-term tolerance and sustainability Tirzepatide May Be a Better Fit For: Individuals with significant insulin resistance Those who did not respond adequately to GLP-1 therapy alone People who tolerate incretin-based medications well Response is highly individual
Minimum goal: 0.8g per pound of goal body weight Optimal range: 90-120g total daily protein Distribution: 20-30g per meal, 4-6 meals daily Sources: Greek yogurt, cottage cheese, eggs, lean poultry, fish, protein powder Managing Reduced Appetite The appetite suppression from Retatrutide creates both opportunity and challenge
Endpoints for the study included changes in ALT levels, BMI Z-score and weight prior to GLP1-RA treatment vs
Insurance Coverage Differs Widely Across Options Some alternatives like Contrave or phentermine-topiramate carry lower out-of-pocket costs and broader insurance approval compared to newer GLP-1 or GIP drugs
The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) is a study comparing sitagliptin with placebo in diabetic patients with a previous history of cardiovascular disease
Our policy on illegal activities and regulated goods prohibits the promotion of nasal tanning sprays, and we have removed the videos that you have shared with us. So next time youre scrolling through social media, if you see something that seems too good to be true, it most likely is, let alone a dermatologists nightmare